Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Authors
Keywords
-
Journal
BLOOD
Volume 118, Issue 18, Pages 4817-4828
Publisher
American Society of Hematology
Online
2011-08-18
DOI
10.1182/blood-2011-04-348540
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Modern Therapy of Acute Lymphoblastic Leukemia
- (2011) Renato Bassan et al. JOURNAL OF CLINICAL ONCOLOGY
- CARs on Track in the Clinic
- (2011) Donald B Kohn et al. MOLECULAR THERAPY
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
- (2010) Michael C. Jensen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
- (2010) B. Jena et al. BLOOD
- Adoptive T cell therapy of cancer
- (2010) Malcolm K Brenner et al. CURRENT OPINION IN IMMUNOLOGY
- Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
- (2010) Renier Brentjens et al. MOLECULAR THERAPY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice
- (2009) S. E. James et al. BLOOD
- T-Cell Engineering for Cancer Immunotherapy
- (2009) Michel Sadelain CANCER JOURNAL
- The promise and potential pitfalls of chimeric antigen receptors
- (2009) Michel Sadelain et al. CURRENT OPINION IN IMMUNOLOGY
- Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: “Are We Nearly There Yet?”
- (2009) Gianpietro Dotti et al. HUMAN GENE THERAPY
- Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy
- (2009) Daniel Hollyman et al. JOURNAL OF IMMUNOTHERAPY
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
- Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma
- (2009) Herschel Wallen et al. PLoS One
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
- (2008) B. G. Till et al. BLOOD
- The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma
- (2008) Eleanor J Cheadle et al. BRITISH JOURNAL OF HAEMATOLOGY
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
- (2008) Mark E. Dudley et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic lymphocytic leukaemia
- (2008) G Dighiero et al. LANCET
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
- (2008) Martin A Pule et al. NATURE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started